Comprehensive Study Notes on Advanced Liposomal Therapeutics
Foundations and Historical Evolution of Liposomal Nanomedicine
Institutional and Academic Context:
- Research conducted at the University of Chieti-Pescara, located in central Italy, operating across two primary campuses: the Chieti campus (main landscape campus) and the Pescara campus.
- Academic domain spans applied chemistry, pharmacy, and hospital pharmacy. Career trajectory evolved from Master's thesis research on antibacterial liposomes into a hospital pharmacy residency, a PhD in Pharmaceutical Sciences, and an Associate Professorship.
Bio-Inspired Scientific Design:
- Nature provides foundational blueprints for engineered scientific systems.
- Atmospheric hail serves as a natural structural analog to engineered frozen confections like lemon ice.
- Avian eggs serve as structural inspirations for hollow chocolate confections.
- Biological cell membranes serve as the direct inspiration for synthetic liposomal vesicles.
Biological Membrane Analogy:
- Living cells feature amphiphilic phospholipid bilayers enclosing defined intracellular compartments and organelles.
- Liposomes directly replicate this structural paradigm, forming enclosed, spherical synthetic lipid bilayers around aqueous compartments.
Historical Development (1964):
- Alec Bengman introduced the foundational concept of synthetic lipid vesicles, initially describing them as "magic droplets" or spheroliths.
- Bengman's Hypothesis: Biological cell membranes possess defined phospholipid compositions and specialized integral membrane transport proteins that selectively regulate the passage of hydrophilic molecules and antibiotics across lipid barriers.
- Proof-of-Concept Experimentation: Bengman extracted lipids from regular avian eggs, mixed them to assemble artificial lipid bilayers, and evaluated solute permeability. He demonstrated that hydrophobic molecules permeate the synthetic lipid assembly while hydrophilic molecules are retained inside unless mediated by specific transport mechanisms.
- Scientific Impact: Bengman's magic droplets transitioned over subsequent decades into advanced, innovative drug delivery systems (DDS).
Stage 1: Basic Liposome Architecture and Passive Gemcitabine Delivery
Structural Versatility of Liposomes:
- Liposomes are spherical nanostructures composed of customizable lipid combinations, enabling precise control over size, surface charge, bilayer fluidity, and surface functionalization.
- Compartmentalization:
- Hydrophilic Core: Encloses water-soluble therapeutic agents.
- Hydrophobic Bilayer: Incorporates lipid-soluble therapeutic agents.
- Surface Functionalization: Can be conjugated with polyethylene glycol (PEG) chains to impart steric stabilization and extend systemic circulation, or modified with specific targeting ligands for personalized medicine.
Lipid Compositional Tuning:
- Formulations incorporate varying combinations of rigid membrane components, fusogenic lipids, fluidic/deformable lipids, and PEGylated lipids.
- Model Hydrophilic Payload: Gemcitabine, a hydrophilic chemotherapeutic drug used in oncological applications.
- Structural Benchmark: Doxil, the first clinically approved liposomal drug formulation.
Physicochemical Characterization & Particle Size:
- Engineered formulations ranged in size from to .
- Formulation B and C Liposomes: Exhibited narrow size distributions centered around .
- Formulation A: Incorporated oleic acid as a fluidifying lipid component, increasing vesicle size to .
In Vitro Drug Release Kinetics:
- Systematic chemical analysis demonstrated that PEGylated liposomes (Liposome C) provided sustained release of Gemcitabine over a period of compared to non-PEGylated or highly fluidic lipid variants.
In Vitro Cellular Accumulation (Caco-2 Model):
- Evaluated in static in vitro models using Caco-2 colon cancer cells.
- Free Gemcitabine: Exhibited minimal intracellular drug accumulation.
- PEGylated Liposomes: Significantly enhanced intracellular Gemcitabine accumulation.
- Kinetics: Maximum intracellular accumulation was achieved within the first , followed by sustained intracellular retention monitored up to .
Stage 2: Transition from In Vitro to In Vivo & EPR Effect
Microenvironmental Discrepancies:
- Static in vitro cell cultures fail to replicate complex pathological tumor microenvironments encountered in vivo.
- Pathological Features of In Vivo Solid Tumors:
- Extensive tumor angiogenesis leading to hypervascularization.
- Fenestrated, structurally abnormal arterial blood vessels with enlarged inter-endothelial gaps.
- Impaired lymphatic drainage resulting in elevated interstitial fluid pressure.
- Altered extracellular pH (acidic microenvironment) and altered extracellular matrix composition.
Enhanced Permeability and Retention (EPR) Effect:
- Long-circulating nanoparticles with diameters smaller than endothelial pore cutoffs passively extravasate through fenestrated tumor blood vessels into the interstitial space.
- Lack of efficient lymphatic drainage prevents nanoparticle clearance, trapping them within the tumor microenvironment for localized, passive accumulation.
Evaluation in 3D Xenograft Animal Models:
- Formulations evaluated included Doxil-like PEGylated liposomes incorporating PEG chains.
- Tested Tumor Models: Xenograft models of anaplastic thyroid cancer and pancreatic cancer.
Anaplastic Thyroid Cancer In Vivo Outcomes:
- Anaplastic thyroid cancer represents an extremely aggressive malignancy.
- Liposomal Gemcitabine was administered at a dosage lower than the standard therapeutic dose of free Gemcitabine (Gemsar).
- Results: Achieved equivalent reductions in tumor volume and tumor weight compared to high-dose free Gemcitabine.
- Therapeutic Benefit: Localized passive accumulation delivers comparable efficacy at a fraction of the drug mass, minimizing off-target toxicity to healthy tissues.
Pancreatic Cancer In Vivo Outcomes:
- Evaluated across two distinct pancreatic cancer cell lines exhibiting high and low therapeutic responsiveness.
- Demonstrated dose-dependent and time-dependent cytotoxicity at low micromolar concentrations in vitro.
- In vivo xenograft models confirmed significantly increased overall survival rates in treated animals.
Stage 3: Multi-Drug Co-Encapsulation Strategies
Rationale for Combination Delivery:
- Standard oncological regimens rely on multi-drug chemotherapy cocktails. Encapsulating multiple chemotherapeutics within a single liposomal vehicle ensures synchronized pharmacokinetics and localized co-delivery.
Dual-Drug Liposomal Architecture:
- Hydrophobic Payload: Paclitaxel embedded directly within the lipid bilayer.
- Hydrophilic Payload: Gemcitabine loaded inside the central aqueous core.
Physicochemical & Clinical Imperatives for Drug Selection:
- Paclitaxel: Highly lipophilic with extremely poor water solubility. Clinical formulations (Taxol) require Cremophor EL (polyoxyethylated castor oil) as a solubilizing vehicle, which causes severe patient hypersensitivity and systemic toxicity.
- Gemcitabine: Highly water-soluble but suffers from a short systemic half-life and rapid metabolic degradation upon intravenous injection.
Formulation Characteristics:
- PEGylated dual-loaded liposomes engineered to an average diameter of .
In Vivo Efficacy in Breast Cancer Lung Metastasis:
- Evaluated via systemic intravenous (IV) injection in breast cancer lung metastasis mouse models, monitoring tumor burden via chemiluminescence imaging.
- Outcomes at Day 35: Dual-loaded liposomes induced partial or complete remission of lung metastatic tumor masses.
- Survival Rate: Animal survival increased to approximately , significantly outperforming control groups treated with single free drugs, drug mixtures, empty liposomes, or phosphate-buffered saline (PBS).
- Histological Tissue Analysis: Post-mortem evaluation confirmed structural restoration of healthy pulmonary tissue architecture in the dual-loaded liposome group.
Stage 4: Active Receptor-Targeted Liposomes and LINtt1 Dual-Targeting
Targeted Delivery Paradigms:
- Passive Delivery: Relies entirely on pathological tissue features (EPR effect, vascular fenestrations, acidic pH, immune cell recruitment).
- Active Delivery: Employs surface-conjugated targeting ligands (peptides, antibodies) or external physical stimuli to direct specific interactions with target cell surface receptors.
LINtt1 Dual-Targeted System Development:
- Developed in collaboration with Helder Santos (University of Helsinki) and Nicola d'Avanzo (University of Catanzaro).
- Disease Model: and breast cancer models.
- Targeting Ligand: LINtt1 peptide (a member of the ERGD peptide family).
- Dual Receptor Targets:
- Neuropilin-1 (NRP-1) / P32 receptors overexpressed on breast cancer cells.
- P32 receptors overexpressed on M2 tumor-associated macrophages (protumorigenic macrophages that drive tumor inflammation and growth).
- Dual Drug Payload:
- Sorafenib: Hydrophobic multi-kinase inhibitor incorporated into the lipid bilayer.
- Doxorubicin Hydrochloride: Hydrophilic anthracycline loaded into the aqueous core.
In Vitro 2D Cytotoxicity:
- LINtt1-targeted dual-drug liposomes demonstrated pronounced cytotoxic activity across sub-micromolar concentration ranges, superior to free drug combinations or non-targeted formulations.
3D Spheroid Penetration Mechanism:
- Multicellular spheroids were structured into concentric zones: an outer proliferating zone, a middle creation zone, and an inner necrotic core.
- Immunofluorescence Tracking: LINtt1-targeted liposomes bound the outer proliferating zone, migrated through the creation zone, and penetrated into the necrotic core, halting cell proliferation across all spheroid layers.
In Vivo Active Targeting Validation:
- Conducted in anaplastic thyroid cancer xenograft models using tritiated () labeled liposomal vehicles and tritiated drug payloads.
- Within post-IV administration, tritiated LINtt1-liposomes accumulated selectively at the tumor site.
- Resulted in marked reductions in final tumor volume and tumor weight compared to saline solution or non-targeted liposomes.
Stage 5: Advanced Surface Modification: Super-Stealth Liposomes and Post-Insertion PEGylation
Limitations of Standard Monomeric PEG-Lipids:
- Commercial PEGylated liposomes utilize linear PEG conjugated to a single lipid anchor (e.g., single DSPE chain).
- Enzymatic or mechanical cleavage in vivo causes loss of the PEG coat within post-injection.
- Cleavage exposes "bare" liposomes, leading to rapid opsonization, immune recognition by macrophages, and hepatic uptake/clearance.
- Pre-manufactured non-PEGylated clinical formulations cannot be retrofitted post-production.
Engineering Innovations:
- Super-Stealth Dendronic PEG-Lipids: Synthesized branched dendron structures (beta-glutamic acid building blocks) coupling a single linear PEG chain to multiple lipid anchors: 2-DSPE (dual anchor) or 4-DSPE (quadruple anchor) units.
- Post-Insertion PEGylation: Co-incubation of pre-formed small unilamellar vesicles (SUVs) with PEGylated micelles at temperatures above the lipid bilayer gel-to-liquid phase transition temperature (), inserting PEG-lipids post-manufacture without disrupting payload integrity.
Pharmacokinetics & Organ Distribution:
- Single-Anchor PEG Liposomes: Experience rapid PEG detachment within , shifting distribution predominantly to the liver with low blood retention.
- Super-Stealth Dendronic Liposomes: Multi-anchor dendronic PEG constructs remain stably attached to the liposome surface for at least (1 week) post-injection.
- Organ Clearance Shift: Demonstrates minimal liver uptake paired with prolonged systemic blood circulation.
In Vivo Therapeutic Outcomes (2025 Study):
- Tested in a breast cancer lung metastasis mouse model over 5 weeks of treatment.
- Super-Stealth liposomes induced profound tumor regression, resulting in tiny, highly suppressed residual tumor masses.
- Long-Term Survival (): Achieved a overall survival rate without adverse side effects, compared to a survival rate for free drug treatments and survival at for control groups.
Stage 6: External Stimuli-Responsive Systems: Hyperthermia and Nanochannel Implantable Chips
Approach 1: Laser-Induced Mild Hyperthermia (Thermal Ablation):
- Mechanism: Applied localized near-infrared laser radiation induces mild hyperthermia () within tumor tissue.
- Vascular Alterations: Mild hyperthermia disrupts endothelial integrity in angiogenic tumor microvessels without causing structural breakdown of the liposomal carrier.
- Liposome Stability: Liposomes formulated with Soy Phosphatidylcholine (SPC) possess phase transition temperatures (), maintaining structural vesicle integrity during laser heating.
- In Vivo Pancreatic Cancer Xenograft Outcomes:
- Laser application triggered massive localized extravasation and interstitial accumulation of fluorescent liposomes.
- Combining liposomal Gemcitabine at a lower dose with mild hyperthermia produced significantly greater reductions in tumor mass and volume than a higher dose of free Gemsar.
Approach 2: Implantable Nanochannel Membrane Chips:
- Device Design: A coin-sized implantable microchip containing a nanochannel membrane acting as an electro-responsive gate.
- Operational Control: External electrical stimulation toggles the gate between open and closed states.
- Release Dynamics: Enables controlled, pulsed release of intact Lapatinib-loaded liposomes into target tissue (breast cancer model) without altering liposomal size or integrity.
Stage 7: Advanced Delivery Platforms: Asymmetric Vector Gene Therapy, EV Hybrids, and Shape-Engineered Liposomes
Asymmetric Bilayer Nucleic Acid Delivery Vectors:
- Patented platform technology supported by an Italian Ministry of Health grant.
- Structural Architecture: Asymmetric bilayer vesicle comprising two distinct functional zones:
- Inner Bilayer: Cationic lipid composition optimized for high-efficiency electrostatic complexation of nucleic acids (siRNA, mRNA, DNA).
- Outer Bilayer: Neutral, PEGylated lipid layer providing steric protection and systemic biocompatibility.
- Comparison to Standard Lipid Nanoparticles (LNPs): Unlike solid-core LNPs (e.g., Pfizer/Moderna COVID-19 mRNA vaccines), asymmetric liposomes maintain a defined aqueous lumen, allowing simultaneous co-encapsulation of small-molecule chemotherapeutics alongside genetic payloads.
- Functional Validation: Successfully encapsulated small interfering RNA (siRNA) and delivered it into breast cancer cells, achieving target gene silencing.
Hybrid Extracellular Vesicle (EV)-Liposomes:
- Composition: Chimeric vesicles formed by fusing thermo-responsive liposomes with extracellular vesicles (EVs) isolated from M1 and M2 macrophages.
- Biochemical Integrity: Retains characteristic macrophage EV surface protein markers both before and after fusion with synthetic liposomes.
- Physicochemical Properties: Spherical morphology with diameters below () and stable zeta potential values ensuring physical stability.
- In Vivo Targeting: Intravenous injection of Doxorubicin-loaded hybrid vesicles into breast cancer xenografts yielded selective tumor accumulation while preserving macrophage EV biomarkers in harvested tumor tissues.
Shape-Engineered Discoidal Liposomes:
- Project Lead: Postdoctoral researcher Shamil Pilarissetti.
- Morphological Switch: Reconstituting spherical liposomes into flat, discoidal nanostructures.
- Polymer Reconstitution Mechanism: Uses poly(styrene-co-maleic anhydride) / maleic anhydride-based amphiphilic polymers to drive lipid bilayer shape transformation.
- Dimensions: Discoidal particles engineered to major lateral dimensions of approximately .
- Current Focus: Investigating shape-dependent protein corona adsorption, cellular internalization, and uptake dynamics in lung cancer models, with plans to engineer hybrid discoidal EV-liposomes.